Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) CEO Carole Ben-Maimon purchased 18,050 shares of Larimar Therapeutics stock in a transaction that occurred on Wednesday, November 11th. The stock was bought at an average cost of $2.77 per share, with a total value of $49,998.50. Following the completion of the transaction, the chief executive officer owned 386,326 shares of the company’s stock, valued at $1,070,123.02. The trade was a 4.90% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Larimar Therapeutics Stock Performance
NASDAQ LRMR traded down $0.03 during trading hours on Thursday, hitting $2.70. The company had a trading volume of 1,190,176 shares, compared to its average volume of 2,378,292. The business has a 50 day moving average of $2.97 and a 200-day moving average of $3.77. The company has a market cap of $280.48 million, a PE ratio of -1.38 and a beta of 0.73. Larimar Therapeutics, Inc. has a 1-year low of $1.91 and a 1-year high of $6.42.
Institutional Trading of Larimar Therapeutics
A number of large investors have recently bought and sold shares of the business. AIGH Capital Management LLC purchased a new position in Larimar Therapeutics during the 3rd quarter worth $5,911,000. WINTON GROUP Ltd purchased a new stake in shares of Larimar Therapeutics in the second quarter valued at about $160,000. Engineers Gate Manager LP purchased a new stake in shares of Larimar Therapeutics in the second quarter valued at about $69,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Larimar Therapeutics during the second quarter worth about $27,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Larimar Therapeutics during the second quarter worth about $346,000. Institutional investors and hedge funds own 91.92% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on LRMR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Leerink Partners initiated coverage on Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating on shares of Larimar Therapeutics in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $10.33.
Read Our Latest Analysis on Larimar Therapeutics
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
See Also
- Five stocks we like better than Larimar Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
